Background. Preoperative detection of RAS mutations can contribute to cancer risk assessment in indeterminate thyroid nodules, although RAS is not always associated with malignancy. Methods. Fine-needle aspiration samples classified in 1 of 3 indeterminate cytology categories were prospectively tested for N-, H-, and K-RAS mutations using next-generation sequencing assay. Results. In the study, 93 patients with 94 nodules had preoperative RAS detected, of whom 86 patients had an operation (69% total thyroidectomy, 29% lobectomy). In total, 76% of RAS-positive nodules were malignant and follicular variant papillary thyroid cancer was the most common cancer type (83%). HRAS mutations had the greatest risk of cancer (92%) followed by NRAS (74%) and KRAS (64%; P = .05). No preoperative variables were associated with malignancy including age (P = .07), sex (P = .49), RAS isoform (P = .05), mutational allelic frequency (P = .49), nodule size (P = .14), cytology category (P = .63), or ultrasound bilaterality (P = .24), multifocality (P = .23), or presence of $1 suspicious feature (P = .86). Only 60% of patients with a unifocal nodule on ultrasound had single focus low-risk encapsulated follicular variant papillary thyroid cancer or benign disease. Conclusion. Preoperative RAS mutation detection in thyroid nodules carries a substantial risk of cancer with a greater risk associated with HRAS and NRAS. Most RAS malignancies are follicular variant papillary thyroid cancer, which may inform the extent of operation. (Surgery 2017;161:168-75.) 
Background. Preoperative detection of RAS mutations can contribute to cancer risk assessment in indeterminate thyroid nodules, although RAS is not always associated with malignancy. Methods. Fine-needle aspiration samples classified in 1 of 3 indeterminate cytology categories were prospectively tested for N-, H-, and K-RAS mutations using next-generation sequencing assay. Results. In the study, 93 patients with 94 nodules had preoperative RAS detected, of whom 86 patients had an operation (69% total thyroidectomy, 29% lobectomy). In total, 76% of RAS-positive nodules were malignant and follicular variant papillary thyroid cancer was the most common cancer type (83%). HRAS mutations had the greatest risk of cancer (92%) followed by NRAS (74%) and KRAS (64%; P = .05). No preoperative variables were associated with malignancy including age (P = .07), sex (P = .49), RAS isoform (P = .05), mutational allelic frequency (P = .49), nodule size (P = .14), cytology category (P = .63), or ultrasound bilaterality (P = .24), multifocality (P = .23), or presence of $1 suspicious feature (P = .86). Only 60% of patients with a unifocal nodule on ultrasound had single focus low-risk encapsulated follicular variant papillary thyroid cancer or benign disease. Conclusion. Preoperative RAS mutation detection in thyroid nodules carries a substantial risk of cancer with a greater risk associated with HRAS and NRAS. Most RAS malignancies are follicular variant papillary thyroid cancer, which may inform the extent of operation. THYROID CANCER is the most common endocrine malignancy, and its reported incidence is on the rise. 1 Although thyroid nodules can be detected in up to 50% of otherwise healthy patients by age 60 years, only 5-15% of thyroid nodules are malignant. 2 Since its introduction in the 1970s, initial evaluation of thyroid nodules using ultrasound (US) and fine-needle aspiration (FNA) biopsy is well established and has decreased the number of patients requiring operation while increasing the likelihood of thyroid malignancy in patients who undergo operation. 3 However, cytology remains unable to diagnose all thyroid malignancies preoperatively and for the ;20-25% of biopsy results that are indeterminate, operation is still often needed for histologic evaluation.
Activating mutations of RAS in thyroid epithelial cells were first reported in the 1980s, but only recently have been implicated directly as early and frequent events in transformation and proliferation of thyroid carcinoma. 4 RAS represents the second most common genetic mutation identified in thyroid cancer and includes a family of 3 highly homologous isoforms: NRAS, KRAS, and HRAS. 5 Point mutations in codons 12, 13, and 61 produce oncogenic alleles and cause loss of intrinsic GTPase activity, leading to constitutive activation of RAS-mediated MAPK and phosphatidylinositol 3-kinase/Akt (or protein kinase B) pathway signaling.
The diagnostic and prognostic importance of RAS mutations is not fully defined because these mutations have been reported not only in thyroid cancers, but also in benign follicular adenomas (FA). 7 In tumors of follicular cell origin, RAS mutations essentially are restricted to FA, follicular thyroid cancer (FTC), and follicular-variant papillary thyroid cancer (FVPTC), which are difficult to differentiate as benign or malignant based on cytology alone, and therefore often carry an indeterminate cytologic diagnosis on preoperative FNA biopsy. 8 In a series of 67 prospectively identified RAS-positive thyroid nodules, cytology was malignant in 3%, benign in 3%, and indeterminate in 94%. 9 Another large series inclusive only of nodules with indeterminate cytology found that using the 7-gene panel RAS was the most common mutation detected (72%), and when RAS was detected preoperatively, the probability of malignancy was 85%. 10 Most RAS mutations have correlated to histologically low-grade FVPTC, but they also occur in other cancer types including FTC, poorly differentiated, and anaplastic thyroid cancer, and even medullary thyroid cancer. 9, 11, 12 Recently, next-generation sequencing (NGS) has been introduced as a sensitive and reliable method for detecting RAS and other mutations in thyroid FNA samples. 13, 14 In this study, we evaluated a large series of cytologically indeterminate thyroid nodules, which tested positive for RAS mutations preoperatively by NGS with the aim of identifying variables associated with histologic outcome that may be used help guide the extent of initial thyroidectomy.
MATERIALS AND METHODS
Study cohort. FNA biopsy results classified in 1 of 3 indeterminate cytology categories: atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS), follicular neoplasm (FN), and suspicious for malignancy (SUSP) were tested prospectively for N-, H-, and K-RAS mutations as part of routine clinical practice since 2008. 15 After University of Pittsburgh Medical Center Quality Improvement Institutional Review Board approval (QIIRB#441), we retrieved and examined the records associated with all nodules with indeterminate cytology and with a positive RAS mutation from September 2013 to June 2015. Clinicopathologic data were retrospectively assessed for each case. Radiology reports and images were reviewed. US bilaterality was defined as the presence of $1 nodule of any size in each lobe, while US multifocality was defined as the presence of >1 nodule of any size. The presence of $1 of the following established sonographic features was considered suspicious: marked hypoechogenicity, loss of echogenic halo, irregular border, microcalcifications, and taller-than-wide shape. All patients in the present study have not been previously described.
Mutational analysis using next-generation sequencing. At the time of initial ultrasoundguided FNA biopsy and after preparation of cytology slides, a portion of the specimen was collected for potential molecular analysis and stored at À208C. For cytologically indeterminate specimens, nucleic acids were isolated using the Compact MagNA Pure Instrument (Roche Molecular Biochemicals, Indianapolis, IN). Samples were tested using NGS on the Ion Torrent PGM or Ion Proton (Life Technologies, Carlsbad, CA) and the ThyroSeq panel, as previously described.
14 The analytic sensitivity of the assay was ;3% mutant alleles, but the clinical sensitivity was set at mutational allelic frequency (AF) $10% (eg, 10% of tested cells contain a mutant allele). 16 Mutation detection was defined as "low level" when mutational AF was <10%.
Statistical analysis. Statistical analysis was performed at a 95% confidence interval by using v 2 for categorical data, unpaired t test for comparison between means, Mann-Whitney U test for unmatched, nonparametric continuous data. All analyses were performed using SPSS statistical software (version 22; SPSS Inc, Chicago, IL).
RESULTS
During the study interval, 93 patients with available clinical records had 94 RAS-positive nodules. There were approximately 2,590 patients with indeterminate cytology that had molecular testing performed during the study period and the rate of RAS-positive nodules was 3.6%. The RAS mutation was identified at a low AF of <10% in 23/94 nodules (24%) and at a high AF of $10% in 71 (76%) nodules. Overall, NRAS mutations were most common and were found in 46 (49%) nodules with the majority occurring in codon 61 (n = 45). HRAS mutations were identified in 28 (30%) nodules of which 24 were in codon 61. KRAS mutations were detected in 20 (21%) nodules and 12 were in codon 12/13. Histology was unavailable for 7 patients who elected for active surveillance (mean follow-up 0.9 months, range 0-24 months). These patients either declined operation or had medical comorbidities that precluded operation. Of the remaining 86 patients with 87 nodules, 59 (69%) had total thyroidectomy, 25 (29%) had thyroid lobectomy, and 2 had completion thyroidectomy after initial lobectomy performed 15 and 1.5 years prior (Fig) .
Malignancy was diagnosed in 66/87 (76%) of RAS-positive resected nodules. The greatest risk of malignancy was associated with HRAS-positive nodules (92%) followed by NRAS (74%) and KRAS (64%, P = .05). In nodules with a low mutational AF, the risk of malignancy was equivalent to nodules with a high mutational AF (67% vs 78%, P = .49). Additional codons tested with NGS that were not previously tested were HRAS codon 12/13, KRAS codon 61, and NRAS codon 12/13. In total, 11/87 (12.6%) nodules had a detected mutation in one of these additional RAS codons including 3 nodules with HRAS codon 13, 7 with KRAS codon 61, and 1 with an NRAS codon 12 mutation. In these 11 nodules, 8 were malignant and the majority of these were KRAS codon 61-positive (6, 75%).
The rates of malignancy in the RAS-positive nodules were similar in all 3 indeterminate cytology categories (Table I , P = .63). The most common cancer type was FVPTC (n = 55, 83%), of which 49/55 (89%) were encapsulated. Other RAS cancer types included classic variant PTC (n = 8, 12%) and poorly differentiated/anaplastic thyroid cancer (n = 3, 5%; Table II) . Of the 3 patients with poorly differentiated/anaplastic thyroid carcinoma, 1 had preoperative computed tomography with evidence of tracheal invasion, and 1 presented with a rapidly enlarging thyroid and cervical lymphadenopathy. The third patient had a mildly hypoechoic nodule without suspicious features on US. The 2 poorly differentiated thyroid cancers were NRAS-and HRAS-positive with mutational AF >40%, and 1 had a coexistent TERT promoter mutation. The anaplastic thyroid cancer was NRASpositive, had a mutational allelic frequency of 15%, and mutations in TERT, E1FIAX, and p53 also were identified.
The demographic and preoperative factors for the 86 patients with 87 RAS-positive nodules are shown in Table III . On univariable analysis, age (P = .07), sex (P = .49), RAS isoform (P = .05), allelic frequency (P = .49), nodule size (P = .14), or cytology category (P = .63) were not predictive of malignancy. No US feature was predictive of RAS malignancy including bilaterality (P = .24), multifocality (P = .23), or presence of $1 suspicious US feature (P = .86; Table III) .
We examined additional histologic outcomes to assess appropriate extent of initial operation. In 59 patients who had total thyroidectomy, bilateral cancers were diagnosed in 17 (29%) patients. A single focus of RAS-positive low-risk encapsulated FVPTC or benign disease on final operative pathology was present histologically in the remaining 28/59 (47%) patients. Among the 25 patients who had lobectomy, no additional operation was needed for 15 (60%) who had either benign disease or low-risk encapsulated FVPTC (Fig) . Overall, when considering the 30 patients with a unilateral nodule on preoperative US who ideally would have been a candidate for initial lobectomy, 18 (60%) had histologic single focus low-risk encapsulated FVPTC (n = 12, 67%) or benign disease (n = 6, 33%), and lobectomy alone would have been sufficient extent of operation.
One patient with NRAS-positive anaplastic thyroid carcinoma developed multisystem organ failure and was transitioned to comfort care on postoperative day 3. Of the remaining 65 patients with RAS-associated malignancy, 14 (22%) received radioiodine ablation, including 11 who had total thyroidectomy and 3 who had lobectomy followed by completion thyroidectomy. On short-term follow-up of 6-24 months, there have been no recurrences to date in these 65 patients.
The present series is not large, and we were interested in the cumulative malignancy rate of RAS lesions since 2008. 15 The compiled histology for all consecutive patients (n = 278) from September 2008 to June 2015 who had both preoperative indeterminate FNA biopsy results and a RAS mutation was calculated and may be seen in Table IV . 15 RAS testing was performed using 2 different techniques including real-time polymerase chain reaction and fluorescence melting curve analysis (n = 191 nodules) and next-generation sequencing as discussed above (n = 87 nodules).
Overall, during an 8-year period of observation, any RAS mutation with indeterminate cytology had an 81% risk of malignancy. In this cumulative series, the risk of malignancy differs significantly by isoform and was greatest in HRAS-positive nodules (94%), followed by NRAS-positive nodules (83%), and KRAS-positive nodules (50%, P < .001).
Although FVPTC was again the most common histologic variant, poorly differentiated/anaplastic cancers were seen with each of the 3 RAS isoforms. Indeterminate nodules with NRAS and HRAS mutation were associated with similar types of histologic cancer (P = .3), but both differed from KRAS-associated cancers (P = .002). In addition, KRAS-associated cancers were more likely to be classic PTC (15%) and FTC (15%). Poorly differentiated/anaplastic cancers were rare as expected (n = 4), and were seen with NRAS and HRAS mutations while 2 medullary thyroid cancers were associated only with KRAS and HRAS mutations (Table IV) .
DISCUSSION
Use of RAS testing for preoperative risk stratification of nodules with indeterminate FNA biopsy results is controversial. Because RAS is also found in benign follicular adenomas, its ability to predict malignancy preoperatively is sometimes inappropriately discounted. In the present series, preoperative detection of any RAS mutation with indeterminate cytology was associated with a high (76%) risk of histologic cancer, which is equivalent to the risk of cancer associated with a SUSP cytology result.
As previously reported, we also observed that RAS-positive follicular tumors represent a continuum from benign FA to poorly differentiated/ ATC. 9 RAS is present at all stages of tumor differentiation, which is not a characteristic feature of other molecular alterations. 17, 18 Prior studies have supported the role of RAS mutation as an early transformative event associated with step-wise tumorigenesis leading from adenoma to carcinoma. 18 This histologic continuum also suggests that RAS mutations may be critical for the development of invasive histology and, rarely, further progression to ATC. 19, 20 Thus, although 24% of RAS-positive nodules in this report were histologically benign FA, the presence of a known oncogenic mutation may have predisposed these nodules to progress to invasive tumors and, in some rare instances, to dedifferentiated, aggressive tumors.
As the present data demonstrate, although all RAS-positive indeterminate nodules should be considered for operative resection, surveillance of low-risk nodules could potentially be considered, given identifiable predictors. We thus sought to identify preoperative risk factors that may be used to differentiate benign from malignant RASpositive indeterminate nodules. Younger age was associated with malignancy, although this did not reach statistical significance (P = .07). Currently, no preoperative variable seems to be associated with RAS malignancy including male sex, mutational allelic frequency, nodule size, US features, or cytology category. The sonographic characteristics that have been described to be suspicious typically are identified in PTC and rarely seen in FVPTC. 21 We previously reported that the negative predictive value of having at least 1 suspicious US feature, including intranodular hypervascularity, was low 9 and again observed here that US is limited at differentiating malignant from benign RAS-positive nodules.
Interestingly, RAS-positive nodules with SUSP cytology had an 83% risk of cancer, which was equivalent to the risk seen in the AUS/FLUS cytology category (78%). Low cellular yield on FNA biopsy is a common clinical concern and in the absence of molecular testing, a repeated AUS/FLUS cytology result is often an indication for operation. We previously had set the clinically significant mutational AF threshold at 10% (ie, 10% of cells contain a mutant allele). 22 However, for RAS detected at <10% mutational AF, we observed a malignancy rate that was equivalent to detection at >10% mutational AF. It is possible that the significance of detecting a RAS mutation at a low allelic frequency depends also on tumor cellularity, and additional study is needed to determine if low level RAS mutation has a reliably equivalent high risk of cancer in the different categories of indeterminate cytology.
We previously found that the likelihood of malignancy was greatest with HRAS (95.5%), compared with NRAS (86.8%) and KRAS (41.7%) (15) . In the current study, we confirm that highrisk pattern (HRAS 92%, NRAS 74%, KRAS 61%). With NGS, we have been able to expand the number of RAS codons being tested, which here allowed detection of an additional 8/66 (12%) thyroid cancers that would otherwise have been missed (thus potentially altering the relative rates for RAS isoforms). With a cumulative experience using the 2 different testing methodologies, but now inclusive of 278 nodules with preoperative RAS and indeterminate cytology, we can conclude that different RAS isoforms are indeed associated with varying rates of malignancy (HRAS > NRAS > KRAS). Furthermore, although NRAS and HRAS-positive nodules have a high (86-88%) likelihood of being associated with FVPTC, KRASpositive nodules have a lower rate of association with FVPTC (65%) and also can be seen with other cancer types including classic PTC (15%) and FTC (15% ; Table IV) .
With a better understanding of what cancer phenotypes are associated with the different RAS isoforms, preoperative nodule risk stratification could be further improved. In the 2015 American Thyroid Association Guidelines, the recommendations for extent of initial thyroidectomy for a known thyroid cancer 1-4 cm include options for both lobectomy or total thyroidectomy, with or without central compartment lymph node dissection. 23 As observed here, because NRAS and HRAS indeterminate nodules are likely to be FVPTC with no observed instances of central compartment lymph node metastasis, lobectomy alone may be sufficient in the absence of other indications for total thyroidectomy. For the 30 study patients with unilateral RAS-positive nodules who potentially would have been candidates for lobectomy by preoperative features, lobectomy was indeed adequate operation based on histologic findings in most (60%). Initial lobectomy will likely be adequate for an expanding subset of RAS-positive thyroid cancer patients in the future.
Initial total thyroidectomy followed by radioactive iodine ablation is still considered the optimal treatment for patients with a high likelihood of recurrence. 23 In a study by Gupta et al, 9 bilateral cancer was diagnosed in 43% of patients with RASpositive malignancy. In this subsequent series, we observed a lower rate of 29% for patients who had total thyroidectomy. Although nodules that were KRAS-positive had a lower rate of malignancy overall, we observed that the KRAS cancers also seemed to be associated with clinically significant cancers, ie, to be FTC and/or to have extrathyroidal extension or lymph node involvement. The number of KRAS-positive malignancies is still low and ongoing prospective analysis of the KRAS subset is needed. RAS mutations associated with poorly differentiated, anaplastic, and medullary thyroid cancers are uncommon, but this diagnosis should still be considered regardless of which RAS isoform is detected if the clinical history, cytology, and imaging features are consistent with an aggressive subtype.
The limitations of this study include its nature as a single-center experience that cannot account for geographic variations in incidences of thyroid cancer or thyroid cancer subtypes. In addition, our anatomic pathologists were not formally blinded to cytologic or molecular results, which could introduce bias; similarly, the reporting of imaging features can be subject to interobserver variability, and we did not examine if the presence of suspicious sonographic features was another preoperative factor that may have influenced the decision for biopsy or operation. In addition, this series was limited to nodules with operative treatment, which may have contributed to referral bias. The longterm outcome of RAS-positive nodules that are being managed nonoperatively remains unknown.
In summary, detection of a RAS mutation in a cytologically indeterminate thyroid nodule carries a high (76-81%) risk of malignancy. The risk of cancer remains high even if RAS is detected at a low level. Histologic malignancies associated with preoperative RAS usually are encapsulated FVPTC without central compartment lymph node involvement or extrathyroidal extension (74%), but can also be classic or poor-prognosis PTC. The majority (60%) of patients with RAS-positive unifocal nodules on preoperative imaging may be adequately treated by initial lobectomy.
Dr Martha A. Zeiger (Baltimore, MD): Very nicely presented study. And I congratulate you and your group.
Just a couple of points and a few questions. Historically, follicular lesions have been described on a continuum with progression of mutations, and we know that a number of benign tumors harbor the RAS mutations, specifically the follicular lesions, and if you review the literature closely, up to 30% of benign lesions harbor RAS mutations. Given the fact that your pathologist is not always blinded, are these tumors really premalignant benign tumors? Are the benign tumors indolent; they do not metastasize? And should we maybe study these tumors carefully longitudinally to see whether or not indeed they are cancers?
Dr Snegal G. Patel: Thank you Dr Zeiger. That is a wonderful point. Actually, RAS is on a continuum, and we do not know necessarily with these indolent tumors, what happens over time, whether they dedifferentiate or become wholly differentiated. We certainly need to look at that scenario and have a blinded study.
There is a trial, multi-institutional trial, that will blind the pathologists to hopefully answer the question, to take some of the bias away. But in terms of it being a spectrum in the nonoperative management or surveillance of these, that is another study that we certainly need to do to find what is going to happen over time with these RAS positive, even benign lesions, like you are talking about, because it seems to be on a continuum and a spectrum with changes over a long period of time that may be indolent and in some sort of dedifferentiation over time.
Dr Kepal N. Patel (New York, NY): I applaud you for this study, and I really like the fact that you emphasize that these RAS positive indeterminate nodules, most of them are encapsulated follicular variants of papillary cancer, and a lobectomy will be sufficient, but I think some people still often feel these may require a total thyroidectomy, so I am happy about that point.
One question I have for you is as the nomenclature of these tumors continues to evolve and change, so encapsulated noninvasive follicular variant of papillary cancer is now often described as noninvasive follicular tumors with papillary-like features, is that going to change your risk of malignancy? Because now they are no longer even being called cancer. That is question number one.
Question number 2 is, when you look at your in determinant nodules, are you including Bethesda V, the suspicious for malignancy category, as part of your indeterminate group? Because I would be surprised to find RAS mutations in that group. I think the majority of those indeterminate nodules will probably go on to be papillary cancers as opposed to follicular variants, and you will probably see a higher predominance of RAF mutations, not RAS mutations.
Dr Snehal G. Patel: Thank you. Both great questions. The second question, the suspicious category. Although we only had 6 patients in our series and 5 out of 6 were malignant, but that is a very good point, that most go on to be papillary thyroid cancer. Some of these tumors were nonencapsulated follicular variant PTCs, a total of 6 in our cohort. So most were encapsulated follicular variant PTC, but we did see the noninvasive and nonencapsulated follicular variant PTCs which I think, as we study these, we will continue to see them, and as the pathologists really learn and define the nomenclature.
Dr Tobias Carling (New Haven, CT): I have a question on sort of the other spectrum. So we know both from the TCGA data on papillary thyroid cancer as well as our excellent sequencing on anaplastic thyroid cancer which was done, also shown by the Fagin group recently on both poorly differentiated thyroid cancer and anaplastic thyroid cancer, meaning that you have a subset of NRAS mutated thyroid cancers that also carry a mutation in EIF1AX gene, and it seems like there is an association with a more aggressive cancer.
So my question is, in your subset, were you able to check for mutational status that co-segregates with NRAS mutations? And, if so, how would that change your operative extent?
Dr Snehal G. Patel: We had 3 patients total, 2 that were poorly differentiated, 1 that was anaplastic. And 2 of those that were poorly differentiated did have additional TERT mutation identified as well as 1 of them had the EIF1AX mutation that you mentioned, and the anaplastic had a p53 mutation. So that certainly does change your strategy. We knew that information preoperatively, but having that information is certainly useful to know that with the additional mutations that our panel identified, the risk of identifying a more aggressive malignancy is certainly there.
Dr Thomas J. Fahey (New York, NY): I think Dr Patel touched on it a bit, but I think the fact that your pathologists were not blinded is incredibly important. And I wonder if you had some outside review how that would change.
So given that the RAS mutations by patients and many referring physicians are thought of as cancer and require a total thyroidectomy, how do you at Pittsburgh counsel patients who you see with a RAS mutation?
Dr Snehal G. Patel: Thank you, Dr Fahey. It is interesting that the issue that our pathologists are not blinded is certainly one of our biggest limitations which needs to be validated and further studied. I completely agree.
With the new guidelines changing---under the 2009 ATA guidelines, our recommendation was for an upfront total thyroidectomy. However, these new guidelines have certainly changed our thought process to offer a lobectomy for what hopefully are more indolent and benign lesions.
